SUBSCRIBE
SUBSCRIBE
News   Business

Forest Laboratories, Inc. Revises Fiscal Year 2013 Earnings Guidance Primarily Due to Evolving Conditions in the Lexapro / escitalopram Market

June 11, 2012 | 
1 min read
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer, today announced revised FY 2013 earnings guidance.
Earnings
MORE ON THIS TOPIC
Aggressive obstacle from the boss. Concept illustration. Vector illustration
Obesity
Is Metsera Worth The Fuss?
November 5, 2025
 · 
4 min read
 · 
Annalee Armstrong
Business concept illustration of a businessman being pointed by giant fingers
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
November 5, 2025
 · 
5 min read
 · 
Annalee Armstrong
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
 · 
1 min read
 · 
Heather McKenzie
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac